IMMU: Study Shows Cancer Treatment Effective

Immunomedics, Inc. (IMMU) announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 (Y-90) plus low-dose gemcitabine at 200 mg/m2, extended median overall survival (OS) to 11.8 months, more than double the 5.4 months OS in patients treated with a single cycle. Increased Y-90 doses also improved responses; patients receiving a dose of 12 mCi/m2 or higher once a week for 3 weeks reporting a median OS of 8.0 months versus 6.0 months at doses of 9 mCi/m2 or less, once a week for 3 weeks.

Be the first to comment

Leave a Reply

Your email address will not be published.